- Home
- GRFX vs SNTI Comparison
GRFX vs SNTI Comparison
Compare GRFX & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRFX
- SNTI
- Stock Information
- Founded
- GRFX 1981
- SNTI 2016
- Country
- GRFX Hong Kong
- SNTI United States
- Employees
- GRFX N/A
- SNTI N/A
- Industry
- GRFX
- SNTI Biotechnology: Pharmaceutical Preparations
- Sector
- GRFX
- SNTI Health Care
- Exchange
- GRFX Nasdaq
- SNTI Nasdaq
- Market Cap
- GRFX 18.1M
- SNTI 17.8M
- IPO Year
- GRFX N/A
- SNTI N/A
- Fundamental
- Price
- GRFX $1.01
- SNTI $3.13
- Analyst Decision
- GRFX Hold
- SNTI Strong Buy
- Analyst Count
- GRFX 1
- SNTI 1
- Target Price
- GRFX N/A
- SNTI $12.00
- AVG Volume (30 Days)
- GRFX 46.9K
- SNTI 24.0K
- Earning Date
- GRFX 01-01-0001
- SNTI 05-08-2025
- Dividend Yield
- GRFX N/A
- SNTI N/A
- EPS Growth
- GRFX N/A
- SNTI N/A
- EPS
- GRFX N/A
- SNTI N/A
- Revenue
- GRFX $24,184,100.00
- SNTI N/A
- Revenue This Year
- GRFX N/A
- SNTI N/A
- Revenue Next Year
- GRFX N/A
- SNTI N/A
- P/E Ratio
- GRFX N/A
- SNTI N/A
- Revenue Growth
- GRFX N/A
- SNTI N/A
- 52 Week Low
- GRFX $0.71
- SNTI $1.52
- 52 Week High
- GRFX $2.75
- SNTI $16.94
- Technical
- Relative Strength Index (RSI)
- GRFX 43.26
- SNTI 38.94
- Support Level
- GRFX $0.95
- SNTI $2.68
- Resistance Level
- GRFX $1.24
- SNTI $3.56
- Average True Range (ATR)
- GRFX 0.26
- SNTI 0.33
- MACD
- GRFX -0.02
- SNTI -0.04
- Stochastic Oscillator
- GRFX 19.21
- SNTI 31.82
About GRFX Graphex Group Limited each representing 20
Graphex Group Ltd is engaged in the sale of graphene products. It operates in three segments namely, the Graphene Products Segment includes Processing and sale of graphite and graphene-related products; the Landscape Architecture Design Segment includes Providing landscape architecture design; and the catering business focuses on the operation of restaurants. The company derives the majority of its revenue from the sale of graphene products segment.
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with their gene circuit platform technologies to fight challenging diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.